Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/5/2008

CALGARY, June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combina
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics established ... annual meeting drew praise from community leaders from SPIE ... the action “a huge step forward … a lasting ... , The Board of Stakeholders voted to approve in ... its 29 April meeting in Brussels, which was sponsored ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine Group ... 50% enrollment of the total projected enrollment required ... safety and preliminary efficacy of the medical technology ... Knee Osteoarthritis (KOA). To date the trial has ... The Phase I open label clinical research ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... is now using radio frequency identification (RFID) software from ... largest manufacturer of cordless telephones. , ,RFID mandates set ... the supply chain management technology, according to Catalyst. The ... RFID technology into its supply chain environment. , ...
... Wis. - One week before Badger football begins its ... have found a new way to demonstrate their school spirit. ... ones with high-powered microscopes. , ,Last month a team of ... "NanoBucky", an image of the university's mascot made of nanofiber ...
... have a rare opportunity to define public discourse over ... about the emerging technology, a University of Wisconsin-Madison journalism ... public is not going to come to you. You ... make it available where people look," says Dietram Scheufele, ...
Cached Biology Technology:Nanotechnology minimizes UW's beloved mascot 2UW study examines public attitudes on nanotechnology 2
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... decades, scientists have used ancient shorelines to predict the stability ... of a high shoreline from three million years ago, for ... were thought to be evidence of a high sea ... assumption has led many scientists to think that if the ... may do just the same in our modern, progressively warming ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... Maj. Gen. (ret) Dale Meyerrose,Chief Information Officer, ... the plenary session and Greg Garcia, Assistant Secretary ... invited to address the Information Assurance community as ... committee of leaders in the federal IA community ...
... to be good, but sometimes its better to be lucky. ... University in St. Louis, had just completed a census of ... the great flood of 1993 deluged the area, putting the ... provided Sexton with a rare opportunity: His collected data and ...
... Engineers at Rensselaer Polytechnic Institute have developed tools to help ... stem cell research how to quickly test stem cell ... a large supply of healthy, viable stem cells to study ... created methods to study millions of stems cells on devices ...
Cached Biology News:Ecologist finds dire devastation of snake species following floods of '93, '95 2Ecologist finds dire devastation of snake species following floods of '93, '95 3Ecologist finds dire devastation of snake species following floods of '93, '95 4Putting stem cell research on the fast track 2Putting stem cell research on the fast track 3Putting stem cell research on the fast track 4
Request Info...
... Features Provides a buffered anti-freeze ... , Maintains a liquid, low viscosity ... of conjugate is necessary and sampling is ... anti-microbial growth during long-term storage Protect ...
Request Info...
... Tecans GenePaint system, which is based on ... steps required for performing in situ hybridization of ... key step in the study of gene expression, ... cells and tissues and can be used to ...
Biology Products: